Dosage Forms. Tablet: 7.5 mg, 15 mg; Suspension: 7.5 mg/5 mL
Common FDA Label Indication, Dosing, and Titration.
1. Osteoarthritis: 7.5 mg po daily, may titrate to max of 15 mg/d
2. Rheumatoid arthritis: 7.5 mg po daily, may titrate to max of 15 mg/d
3. Juvenile rheumatoid arthritis: Children 2 y and older, 0.125 mg/kg po daily, may titrate to max of 7.5 mg/d
Off-Label Uses. None
MOA. Nonselective inhibitor of cyclo-oxygenase-1 (COX-1) and cyclo-oxygenase-2 (COX-2), and reversibly alters platelet function and prolongs bleeding time.
Drug Characteristics: Meloxicam
Medication Safety Issues: Meloxicam
Drug Interactions: Meloxicam
Adverse Reactions: Meloxicam
Efficacy Monitoring Parameters. Decreased pain and improved range of motion.
Toxicity Monitoring Parameters. CBC, LFTs, SCr, fecal occult blood tests if chronic use. Seek medical attention if severe skin rash, black tarry stools, chest pains, yellowing of eyes or skin, or change in urination.
Key Patient Counseling Points. Take with food or milk to decrease GI upset. For suspension, shake gently before using.
Clinical Pearls. Elderly patients are at increased risk of GI ulceration. Use lowest effective dose for shortest possible duration; after observing initial response, adjust dose and frequency to meet individual patient’s needs.